EP2348968A1 - Procédés et analyses d'évaluation d'un risque cardiaque et d'une ischémie - Google Patents

Procédés et analyses d'évaluation d'un risque cardiaque et d'une ischémie

Info

Publication number
EP2348968A1
EP2348968A1 EP08825246A EP08825246A EP2348968A1 EP 2348968 A1 EP2348968 A1 EP 2348968A1 EP 08825246 A EP08825246 A EP 08825246A EP 08825246 A EP08825246 A EP 08825246A EP 2348968 A1 EP2348968 A1 EP 2348968A1
Authority
EP
European Patent Office
Prior art keywords
cardiac
troponin
cardiac troponin
test subject
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08825246A
Other languages
German (de)
English (en)
Other versions
EP2348968A4 (fr
Inventor
Winton G. Gibbons
Thomas F. Holzman
Phillip A. Lefebvre
Gregory W. Shipp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanosphere LLC
Original Assignee
Nanosphere LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanosphere LLC filed Critical Nanosphere LLC
Publication of EP2348968A1 publication Critical patent/EP2348968A1/fr
Publication of EP2348968A4 publication Critical patent/EP2348968A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Definitions

  • Cardiac troponin T was introduced in the routine laboratory diagnostic work-up in 1989 to sensitively indicate acute myocardial ischaemia (MI).
  • Primary causes of troponin T positivity include MI 5 unstable coronary heart disease, myocarditis, hypertrophic cardiomyopathy, uraemic cardiomyopathy, atrial fibrillation, congestive heart failure, hypotonia, hypovolemia, percutaneous coronary intervention, and ASD closure.
  • troponin I positivity include MI, unstable coronary heart disease, myocarditis, pericarditis, hypertrophic cardiomyopathy, tachycardia, atrial fibrillation, congestive heart failure, increased left ventricular mass, severe aortic valve disease, coronary vasospasm, cardiac contusion, cardiac tamponade, hypertensive crisis, implantable cardioverter defribrillator shocks, electrical cardioversion, percutaneous coronary intervention, ASD closure, radiofrequency ablation, cardiac transplantation, and pacemaker implantation.
  • the most frequency of causes for troponin T positivity when multiple causes are at issue include MI, atrial fibrillation, congestive heart failure, chronic renal insufficiency, percutaneous cardiac interventions, chronic obstructive pulmonary disease, tachycardia, acute stroke, electric cardioversion, dilated cardiomyopathy, increased left ventricular mass, aortic valve disease, and hypertensive crisis.
  • MI atrial fibrillation
  • congestive heart failure chronic renal insufficiency
  • percutaneous cardiac interventions chronic obstructive pulmonary disease
  • tachycardia acute stroke
  • electric cardioversion dilated cardiomyopathy
  • increased left ventricular mass aortic valve disease
  • hypertensive crisis by far the most common single cause for troponin T positivity is MI.
  • Current cardiac troponin assays report one concentration for any and all cardiac troponins having cTnl or cTnT isoforms and their serum carried, metabolized products at one time point per sample. Increasing target incubation
  • the invention provides a method to determine a mammal or other test subject at risk of or suspected of having unstable angina or non-ST elevation myocardial infarction.
  • the method includes detecting the amount of first complexes formed by contacting a first physiological fluid sample from a test subject at risk of or suspected of having acute coronary syndrome and a substrate having one or more moieties that specifically bind cardiac troponin, thereby detecting the concentration of troponin in the first physiological sample.
  • the amount of the first complexes is compared with second complexes formed by contacting a second physiological sample from the test subject from a different time point with a substrate having the one or more moieties that specifically bind cardiac troponin.
  • the rate of increase in cardiac troponin concentrations over time may be indicative of, for example, MI, unstable angina (UA) or non-ST elevation myocardial infarction (NSTEMI).
  • the test subject is a human.
  • the one or more moieties are monoclonal antibodies which are employed to capture, immobilize or detect cardiac troponin.
  • the one or more moieties are polyclonal antibodies, e.g., a composition comprising cardiac troponin-specific polyclonal antibodies is employed to capture, immobilize or detect cardiac troponin.
  • the one or more capture cardiac troponin-specific antibodies are specific for one epitope of troponin and the one or more detection cardiac troponin- specific antibodies bind more than one epitope of troponin. In one embodiment, the one or more capture cardiac troponin-specific antibodies bind more than one epitope of troponin and the one or more detection cardiac troponin-specific antibodies are specific for one epitope of troponin.
  • the method provides for detection of cardiac troponin concentrations of 10 pg/mL or less, e.g., less than about 1 pg/mL, based on calibration to the independently established NIST troponin standard (National Institute of Standards and Technology; see www.nist.gov), e.g., concentrations of 2 fg/niL to 10 pg/mL, 2 fg/mL to 100 fg/mL or 10 fg/mL to 500 fg/mL.
  • NIST troponin standard National Institute of Standards and Technology; see www.nist.gov
  • Such a sensitive assay allows for detection of a test subject that is not at risk of or having a cardiac event, e.g., not at risk of or having acute coronary syndrome, as well as distinguishing between acute coronary syndromes, such as UA and NSTEMI.
  • a cardiac event e.g., not at risk of or having acute coronary syndrome
  • distinguishing between acute coronary syndromes such as UA and NSTEMI.
  • elevated cardiac troponin levels that do not substantially increase over time likely indicate chronic conditions, while a greater rate increase in cardiac troponin levels over time may be indicative of UA or NSTEMI.
  • the time points for comparison may be minutes apart, e.g., 5, 10, 20, or 30 minutes apart, hours apart, e.g., 1, 2, 4, 6, or 8 hours apart, or one or more days apart, or any combination thereof.
  • the rate of increase of cardiac troponin levels in a test subject having NSTEMI is greater than the rate of increase of cardiac troponin levels in a test subject having UA.
  • the complexes are detected with one or more second moieties that specifically bind cardiac troponin linked to a detectable molecule, such as a nanoparticle, an oligonucleotide or barcode.
  • a detectable molecule such as a nanoparticle, an oligonucleotide or barcode.
  • the signal generated by the detectable molecule can be amplified.
  • a silver coating (deposition) on a gold nanoparticle bound to a complex on a substrate can amplify the signal generated by the presence of the gold nanoparticle when exposed to light and a fluorescently labeled primer that hybridizes to an oligo- or polynucleotide bound to a complex on a substrate can be employed to amplify nucleic acid sequences in the oligo- or poly-nucleotide by enzymatic processes.
  • the invention provides a method to detect cardiac troponin concentrations of 10 pg/mL or less.
  • the method includes detecting the amount of first complexes formed by contacting a first physiological fluid sample from a test subject and a solid substrate having one or more cardiac troponin- specif ⁇ c antibodies, thereby detecting the concentration of troponin in the first physiological sample, wherein cardiac troponin concentrations of 10 pg/mL or less are detectable.
  • the method includes comprising comparing the amount of the first complexes with second complexes formed by contacting a second physiological sample from the test subject from a different time point with a solid substrate having the one or more cardiac troponin-specific antibodies, wherein the rate of increase in the amount of cardiac troponin over time is indicative of acute coronary syndrome in the test subject.
  • the method includes providing a mixture comprising a physiological fluid sample from a test subject and a solid substrate having one or more moieties that specifically bind cardiac troponin so as to form a first complex. That complex is contacted with one or more different moieties that specifically bind cardiac troponin and are attached to a detectable molecule. The presence or amount of the detectable molecule is detected or determined, thereby detecting or determining cardiac troponin levels.
  • the method provides for detection of cardiac troponin concentrations of less than 10 pg/mL, e.g., less than 1 pg/mL based on calibration to the independently established NIST troponin standard.
  • the method detects cardiac tropinin levels as low as 5 fg/mL.
  • cardiac tropinin levels as low as 5 fg/mL.
  • a sensitive assay allows for detection of a test subject that is not at risk of or having a cardiac event.
  • the levels of troponin in the test subject not at risk of acute coronary syndrome are less than about 300 fg/mL.
  • the complexes are detected with one or more second moieties that specifically bind cardiac troponin linked to a detectable molecule.
  • the methods described herein also allow for screening for cardiac cytotoxicity, e.g., in a non emergency room type setting.
  • the methods to detect cardiac troponin are employed to screen for the cardiac cytotoxicity of compounds administered to non human animals.
  • a solid substrate comprises a plurality of different physically separated cardiac tropinin-specific binding moieties, e.g., cardiac troponin-specific antibodies that are specific for different epitopes of troponin are each present at different preselected positions on the solid substrate.
  • Contacting the solid substrate with a physiological sample obtained from one or more time points can provide for a profile of the presence and/or amounts of those different epitopes at one or more times.
  • Those profiles may be useful to differentiate between different acute coronary syndromes, prognosis, selection of therapies, or any combination thereof.
  • Other factors which may be considered in the differential diagnosis, outcome or therapy selection include, but are not limited to, gender, ethnicity, age, smoking and/or diabetes.
  • the solid substrate comprises an (first) antibody specific for one epitope of cardiac troponin, e.g., a monoclonal antibody
  • a polyclonal (second) antibody linked to the detectable molecule is employed to detect cardiac troponin bound to the first antibody.
  • the solid substrate comprises a composition comprising (first) antibodies that bind more than one epitope of troponin
  • an antibody that binds to only one epitope of cardiac troponin is employed to detect cardiac troponin bound to the first antibodies.
  • the invention includes methods that employ an epitope-specific assay format to distinguish different forms of troponin and the changes of each form over time, so as to provide a differential diagnosis between UA, NSTEMI, ACS, AMI, and the like, at an earlier time point, which may reduce the need for additional cardiac diagnostic assays. Also included are methods for detecting troponin that are more sensitive, which employ a cutoff and/or slope measurements that may be used to differentiate one population, risk group or diagnosis from another for cardiac events.
  • the system includes a bus;a network interface coupled to the bus; a processor coupled to the bus; a memory coupled to the bus and holding an instruction set executable on the processor to:receive, over the network interface from a client, first and second inputs indicative of detected amounts of cardiac troponin concentrations of respective first and second physiological fluid samples taken at respective first and second time points from a test subject; evaluate the first and second inputs as a function of one or more algorithms held in the memory, the algorithms executable with regard to the first and second inputs to identify one or more cardiac conditions of the test subject; and provide, to the client over the network interface, an output indicative of the one or more identified cardiac conditions of the test subject.
  • Figure IA shows a dose response curves for cTnl concentrations after 30 minute (light gray triangles, Tl), 1 hour (gray squares, T2), or 2 hour cTnl target incubation times (black diamonds, T3).
  • the signal in the fully developed assay increases with the time allowed for the cTnl in the patient sample to come into contact with the capture antibody.
  • the times to proceed from the Tl line to the T2 line to the T3 line depend upon the initial level of cTnl measured in the patient sample, and the assay parameters associated with the reagents in the cartridge (time, temperature, buffers, etc.).
  • antibody 817 may be used as a capture antibody
  • PAlOlO may be used as the detection (probe) antibody.
  • Figure IB shows percent distribution (x-axis) versus measured cTnl concentration (y-axis) of UA, NSTEMI and normal patients determined at blood draw times of 0, 2 and 8 hours with the nanoparticle assay. Arrows high-light the progression of patient populations (UA for example - or NSTEMI) at each blood draw time point.
  • Horizontal line at 2 pg/mL is the cut-off for the nanoparticle assay described herein (cut-off point is defined as the 99th%ile of reference population for the described assay, either the nanoparticle assay or a current commercial assay).
  • Horizontal line at 10 pg/mL is the cut-off for an assay from Biomerieux.
  • Figure 1C shows percent distribution (x-axis) versus measured cTnl concentration (y-axis) of UA, NSTEMI and normal patients determined at blood draw times of 0, 2 and 8 hours with the nanoparticle assay. Arrows high-light the progression of patient populations (UA for example or NSTEMI) at each blood draw time point. Horizontal line at 2 pg/mL is the cut-off for the nanoparticle assay described herein (cut-off point is defined as the 99th%ile of reference population for the described assay, either the nanoparticle assay or a current commercial assay. Horizontal line at 10 pg/mL is the cut-off for an assay from Biomerieux.
  • Figure ID illustrates percent distribution (x-axis) versus measured cTnl concentration (y-axis) of UA, NSTEMI and normal patients determined at blood draw times of 0, 2 and 8 hours with the nanoparticle assay. Arrows high-light the progression of patient populations (UA for example or NSTEMI) at each blood draw time point. Horizontal line at 2 pg/mL is the cut-off for the nanoparticle assay described herein (cut-off point is defined as the 99th%ile of reference population for the described assay, either the nanoparticle assay or a commercial assay). Horizontal line at 10 pg/mL is the cut-off for an assay from Biomerieux.
  • Figure 2 illustrates differential measurement of cTnl epitopes using selected antibodies.
  • Each column of the x-axis represents an anti-troponin Ab bound to the substrate (capture Ab).
  • Each column of the y-axis represents a secondary anti- troponin Ab used to label the target bound to the antibody attached to the substrate.
  • the clone name and troponin binding epitope are listed (e.g., clone 2Bl.9 binds to troponin amino acid residues 41-53).
  • the z-axis represents signal generated with the corresponding pair of antibodies.
  • Figure 3 shows a hypothetical timeline for the generation cTnl epitopes resulting from a cardiac event where troponin is released into the circulation and antibody epitopes are exposed over time as the result of the degradation or metabolic processing by serum proteinases which alters the protein structure and exposes different regions of the troponin protein sequence to the bulk serum.
  • An alternate, less sensitive, non-nanoparticle immunoassay based on detection of the sum of all epitopes rather than the appearance of individual epitopes is shown as a dotted line above the individual epitope graph. Less sensitive assays are unlikely to detect the appearance of individual epitopes and can not resolve the true 99th percentile cut-off for a normal population (which can only be observed with the a more sensitive assays such as the nanoparticle assay).
  • Figure 4 illustrates a multi-time point, multi-metabolite diagnostic algorithm for analysis of the extent (amount) and time course of appearance of cardiac troponin epitopes.
  • Figure 5 shows the distribution of cardiac troponin I levels in 181 normal patient samples collected from 18 to 30 year olds.
  • the troponin values for each patient sample were generated using a standard curve of troponin I spiked into troponin free serum using a nanoparticle-based ultrasensitive troponin assay.
  • Figure 6 A illustrates the proportion of unstable angina patients with a detected positive cardiac troponin I (cTnl) at different time points using the current generation (eg) cTnl assay based upon a previously established cut-point (> 0.10 ng/mL), and the lower limit of detection (>0.04 ng/mL), and a nanoparticle (nano) based cTnl assay using the 99th percentile (0.008 ng/mL), the 10% CV (> 0.002 ng/mL), and the lower limit of detection (0.0005 ng/mL).
  • the current generation eg
  • cTnl assay based upon a previously established cut-point (> 0.10 ng/mL), and the lower limit of detection (>0.04 ng/mL)
  • nanoparticle (nano) based cTnl assay using the 99th percentile (0.008 ng/mL), the 10% CV (> 0.002 ng/mL), and the lower limit of detection
  • Figure 6B shows the timing of detection of myocardial injury in patients with a non-ST elevation myocardial infarction using the current generation (eg) cTnl assay based upon a previously established cut-point (> 0.10 ng/mL), and the lower limit of detection (>0.04 ng/mL), and a nanoparticle (nano) based cTnl assay using the 99th percentile (0.008 ng/mL),and the 10% CV (> 0.002 ng/mL).
  • the current generation eg
  • cTnl assay based upon a previously established cut-point (> 0.10 ng/mL), and the lower limit of detection (>0.04 ng/mL)
  • nanoparticle (nano) based cTnl assay using the 99th percentile (0.008 ng/mL),and the 10% CV (> 0.002 ng/mL).
  • Figure 7A is a graph of mean signal intensity (y-axis) from the ultrasensitive rat troponin assay as a function of troponin target concentration (x-axis). A dose response in signal is observed from 10 to 2500 pg/mL troponin.
  • Figure 7B is a table providing numerical data for each sample tested as part of the target titration.
  • the percent CV was calculated using the six replicate spot measurements used to analyze the mean signal intensity from each assay.
  • the recovered value was calculated based on a linear fit of the 0 to 400 fg/mL data demonstrating 10 fg/mL detection sensitivity.
  • Figure 8 is a logical block diagram of a computing environment according to an example embodiment.
  • Figure 9 is a block diagram of a computing device according to an example embodiment.
  • Figure 10 is a block flow diagram of a computerized method according to an example embodiment.
  • Figure 11 is a table showing patient results with a currently available commercial cTn assay.
  • Figure 12 shows troponin measurements (pg/mL) using the ultrasensitive cTnl assay for 50 normal samples. Specific risk factors are listed, along with body mass index (BMI), ethnicity, gender, and age.
  • BMI body mass index
  • Analyte or "target analyte” is a substance to be detected in a test physiological sample using the present invention.
  • the analyte can be any substance, e.g., a protein, or a set of related proteins, e.g., troponin isoforms and metabolites thereof.
  • Capture moiety is a specific binding member, capable of binding the analyte, which moiety may be in solution or directly or indirectly attached to a substrate.
  • a capture moiety includes an antibody bound to a support either through covalent attachment or by adsorption onto the support surface.
  • ligand refers to any organic compound for which a receptor or other binding molecule naturally exists or can be prepared.
  • ligand also includes ligand analogs, which are modified ligands, usually an organic radical or analyte analog, usually of a molecular weight greater than 100, which can compete with the analogous ligand for a receptor, the modification providing means to join the ligand analog to another molecule.
  • the ligand analog usually differs from the ligand by more than replacement of a hydrogen with a bond which links the ligand analog to another molecule, e.g., a label, but need not.
  • the ligand analog can bind to the receptor in a manner similar to the ligand.
  • the analog could be, for example, an antibody directed against the idiotype of an antibody to the ligand.
  • a capture antibody may have a label that binds another molecule, e.g., the antibody is linked to biotin and strapetavidin is coated onto a substrate.
  • the term "receptor" or "antiligand” refers to any compound or composition capable of recognizing a particular spatial and polar organization of a molecule, e.g., epitopic or determinant site.
  • Illustrative receptors include naturally occurring receptors, e.g., thyroxine binding globulin, antibodies, enzymes, Fab fragments, lectins, nucleic acids, avidin, protein A, barstar, complement component CIq, and the like.
  • Avidin is intended to include egg white avidin and biotin binding proteins from other sources, such as streptavidin.
  • antibody refers to an immunoglobulin which specifically binds to and is thereby defined as complementary with a particular spatial and polar organization of another molecule, including recombinant antibodies such as chimeric antibodies and humanized antibodies.
  • the antibody can be monoclonal or polyclonal and can be prepared by techniques that are well known in the art such as immunization of a host and collection of sera (polyclonal) or by preparing continuous hybrid cell lines and collecting the secreted protein (monoclonal), or by cloning and expressing nucleotide sequences or mutagenized versions thereof coding at least for the amino acid sequences required for specific binding of natural antibodies.
  • Antibodies may include a complete immunoglobulin or fragment thereof, which immunoglobulins include the various classes and isotypes, such as IgA, IgD, IgE, IgGl, IgG2a, IgG2b and IgG3, IgM, etc. Fragments thereof may include Fab, Fv and F(ab') 2 , Fab', and the like. In addition, aggregates, polymers, and conjugates of immunoglobulins or their fragments can be used where appropriate so long as binding affinity for a particular molecule is maintained. Cardiac Troponin
  • the troponins have higher sensitivity which allows for the detection of very small amounts of myocardial necrosis.
  • Acute coronary syndrome encompasses a spectrum of coronary artery diseases, including unstable angina, ST-elevation myocardial infarction (STEMI; often referred to as “Q- wave myocardial infarction”), and non-STEMI (NSTEMI; often referred to as "non-Q-wave myocardial infarction”).
  • ST-elevation myocardial infarction ST-elevation myocardial infarction
  • NSTEMI non-STEMI
  • Non-Q-wave myocardial infarction Differentiating acute coronary syndrome from noncardiac chest pain is a primary diagnostic challenge.
  • Symptoms of acute coronary syndrome include chest pain, referred pain, nausea, vomiting, dyspnea, diaphoresis, and light-headedness. Some patients may present without chest pain. Pain may be referred to either arm, the jaw, the neck, the back, or even the abdomen.
  • Typical angina is described as pain that is substernal, occurs on exertion, and is relieved with rest. Atypical symptoms do not necessarily rule out acute coronary syndrome. However, a combination of atypical symptoms improves identification of low-risk patients. Serum cardiac marker determinations play a vital role in the diagnosis of acute myocardial infarction.
  • Characteristics of the most important serum cardiac markers for acute MI are, for CK, first positive at 3 to 8 hours and peaking at 12 to 24 hours, and in a serial assay has a 95% sensitivity and a 30% positive predictive value; for CK-MB, first positive at 4 to 6 hours, and peaking at 12 to 24 hours, and in a serial assay has 95% sensitivity and a 73% positive predictive value; assays for TnI and TnT, first positive at 4 to 10 hours and peaking at 8 to 28 hours, and for the peak times has a 89% sensitivity has a 72% positive predictive value while earlier times have a 35% sensitivity and 56% positive predictive value (Karras et al., Emerg. Med. Clin. North Am., 19:321 (2001)); Hamm et al., N. Engl. J. Med.,
  • Troponins are found in striated and cardiac muscle. Because the cardiac and skeletal muscle isoforms of troponin T and I differ, they are known as the "cardiac troponins," and are markers for the diagnosis of myocardial injury
  • Troponin T and I generally have similar sensitivity and specificity for the detection of myocardial injury.
  • the cardiac troponins typically are measured at emergency department admission and repeated in six to 12 hours.
  • the cardiac troponins may remain elevated up to two weeks after symptom onset, which makes them useful as late markers of recent acute myocardial infarction.
  • An elevated troponin T or I level is helpful in identifying patients at increased risk for death or the development of acute myocardial infarction (Karras et al, Emerg. Med. Clin. North Am.. 19:321 (2001)). Increased risk is related quantitatively to the serum troponin level.
  • the troponins also can help identify low- risk patients who may be home with close follow-up (Hamm et al., N. Engl. J. Med., 337:1648 (1997).
  • the invention provides sensitive methods and systems to assess cardiac events by detecting cTn levels and/or specific cTn isoforms.
  • cTnl concentrations ⁇ 10-40 pg/mL are undetectable in a clinically useful time frame using current commercially available cTnl assays.
  • cTnl levels in the range of 10 fg/mL-10 pg/mL become measurable using the assays described herein, and the data described herein demonstrate that these ultrasensitive levels have relevance for diagnosing cardiac events.
  • both rapid measurements in typical ranges for acute events i.e., acute myocardial infarction which is measured currently at > 10—40 pg/mL
  • ultrasensitive measurements for earlier and differentiated diagnosis of other cardiac events e.g., between NSTEMI, unstable angina, or earlier detection of AMI
  • the levels of cTn in a patient physiological sample e.g., a physiological fluid sample, such as blood plasma, blood serum or saliva, or a tissue biopsy, e.g., are tested at two time points, for instance, using the same instrument.
  • a rapid test (a few minutes) measures levels (e.g., 10-100 pg/mL) currently requiring tens of minutes in state-of- the-art instruments. A positive reading for the rapid test likely obviates the need for further tests. If the first (rapid) test is negative, the second test may be conducted for a longer period of time (e.g., tens of minutes) to resolve cTnl levels (e.g., «10 pg/mL) not currently detectable by state-of-the-art instruments.
  • the slope of the change in cTnl levels may be employed for a faster cardiac risk assessment or diagnosis of acute coronary syndrome (ACS) and/or a more differentiated diagnosis, e.g., between non-ST-elevation myocardial infarction (NSTEMI) and unstable angina (UA) when compared to the current practice of using a cutoff threshold to establish acute myocardial infarction.
  • the change in cTnl levels may be obtained using two successive blood draws or a more resolved assay (i.e., an assay where the sample is contacted with a capture moiety for a longer period of time) combined with a successive blood draw.
  • one or more different types of capture moieties that bind to cardiac troponin may be immobilized onto the surface of a substrate, e.g., before contact with the sample.
  • the capture moiety may be bound to the substrate by any conventional means including one or more linkages between the capture probe and the surface or by adsorption.
  • one or more different types of capture moieties that bind to cardiac troponin are contacted with the sample and in one embodiment, the resulting complex is immobilized onto the surface of a substrate. In another embodiment, the complex is not immobilized onto a substrate.
  • the capture moiety and cardiac troponin may be specific binding pairs such as antibody-antigen or receptor-ligand.
  • any target analyte-capture moiety complex is then detected, e.g., using probes having a detectable molecule.
  • the detectable molecule is a nanoparticle
  • the presence of the nanoparticle may be detected by flow-based methods or detection may be enhanced by silver staining.
  • Silver staining can be employed with any type of nanoparticle that catalyzes the reduction of silver.
  • the nanoparticles are made of noble metals (e.g., gold and silver). See Bassell et al., X, Cell Biol, 126:863 (1994); Braun-Howland et al., Biotechniques, 13:928 (1992).
  • Silver staining has been found to provide a large increase in sensitivity for assays employing a single type of nanoparticle.
  • one or more layers of nanoparticles may be used, each layer treated with silver stain as described in PCT/USOl/21846.
  • selection of various epitope- or modification-specific cTn antibodies allow for differential measurement of these various forms.
  • the assay combines various cTn antibodies to more accurately detect total cTnl by detecting different forms simultaneously.
  • the assay includes simultaneous detection of each individual cTnl form in a single test on a single sample based on multiple epitope detection. The results of such an assay may be useful to fine-tune the diagnosis or for additional diagnosis of cardiac events.
  • the invention provides an assay that differentiates between acute coronary syndromes such as UA, NSTEMI, and/or acute myocardial infarction (AMI) based on the change in cTn levels over a relatively short time frame (e.g., over 5, 10, 15, 20, 25, 30 or more minutes, but less than 10 hours) or epitope-mediated troponin metabolite discrimination.
  • acute coronary syndromes such as UA, NSTEMI, and/or acute myocardial infarction (AMI) based on the change in cTn levels over a relatively short time frame (e.g., over 5, 10, 15, 20, 25, 30 or more minutes, but less than 10 hours) or epitope-mediated troponin metabolite discrimination.
  • Detection may employ a silver-amplified antibody probe array, a biobarcode assay, or a flow-based detection of nanoparticles (see, e.g., Nam et al., Science, 301:1884 (2003); Bao et al, Anal. Chem.. 78:2055 (2006); U.S. Patent Nos.
  • a solid substrate such as a microarray slide, magnetic bead, microwell plate or test tube is functionalized with different specific capture moieties (e.g., monoclonal antibodies) capable of specifically capturing the target or form of interest, e.g., at a defined epitope.
  • specific capture moieties e.g., monoclonal antibodies
  • a sample is allowed to contact the substrate for variable times which enables different levels of target detection.
  • a second set of nanoparticle-based detection probes functionalized with complementary moieties capable of specific and defined attachment to the captured target is introduced into the assay (note variations of this principle that are well established also can be used, including biotin-streptavidin interactions).
  • the signal of each unique capture moiety amy be amplified by silver deposition on captured gold probe (array-based assay), unique reporter biobarcode oligos are released and detected on an array (biobarcode assay) or variable encoded probes are released and detected by laser-based flow.
  • the assay results are read by a detection system (e.g., VerigeneID or a Tecan scanner) and an algorithm determines the quantity of each individual moiety and calculates the relative and total results over time. Additional samples taken over time are incorporated to determine and report any changes in quantity and slope of total and/or specific cTnl forms.
  • a detection system e.g., VerigeneID or a Tecan scanner
  • Additional samples taken over time are incorporated to determine and report any changes in quantity and slope of total and/or specific cTnl forms.
  • the present invention also relates to methods that utilize oligonucleotides as biochemical barcodes for detecting cardiac troponin in solution.
  • the approach takes advantage of protein recognition elements functionalized with oligonucleotide hybridization events that result in the aggregation of gold nanoparticles which can significantly alter their physical properties (e.g. optical, electrical, mechanical).
  • Each protein recognition element can be encoded with a different oligonucleotide and a physical signature associated with the nanoparticles that changes upon melting to decode a series of analytes in a multi-analyte assay, e.g., to detect specific epitopes of cardiac troponin.
  • a particle complex probe comprising a particle having oligonucleotides bound thereto, a DNA barcode, and a oligonucleotide having bound thereto a specific binding complement to a target analyte, wherein the DNA barcode has a sequence having at least two portions, at least some of the oligonucleotides attached to the particle have a sequence that is complementary to a first portion of a DNA barcode, the oligonucleotides having bound thereto a specific binding complement have a sequence that is complementary to a second portion of a DNA barcode, and wherein the DNA barcode is hybridized at least to some of the oligonucleotides attached to the particle and to the oligonucleotides having bound thereto the specific binding complement; contacting the sample with a particle complex probe under conditions effective to allow specific binding interactions between the analyte and the particle complex probe and to form an aggregated complex in the presence of analyte.
  • Aggregate formation is then determined.
  • aggregates are produced as a result of the binding interactions between the particle complex probe and the target analyte.
  • the aggregates may be detected by any suitable means.
  • Each type of particle complex probe may contain a predetermined reporter oligonucleotde or barcode for a particular target analyte.
  • nanoparticle aggregates are produced as a result of the binding interactions between the nanoparticle complex and the target analyte.
  • These aggregates can be isolated and analyzed by any suitable means, e.g., thermal denaturation, to detect the presence of one or more different types of reporter oligonucleotides.
  • These aggregates may be isolated and subject to conditions effective to dehybridize the aggregate and to release the reporter oligonucleotide.
  • the reporter oligonucleotide is then isolated.
  • the reporter oligonucleotide may be amplified by any suitable means including PCR amplification.
  • Analyte detection occurs indirectly by ascertaining for the presence of reporter oligonucleotide or biobarcode by any suitable means such as a DNA chip. After the DNA barcodes are isolated the presence of one or more DNA barcodes having different sequences are detected, wherein the identification of a particular DNA barcode is indicative of the presence of a specific target analyte in the sample.
  • Nanoparticles useful in the practice of the invention include metal (e.g, gold, silver, copper and platinum), semiconductor (e.g., CdSe, CdS, and CdS or CdSe coated with ZnS) and magnetic (e.g., ferromagnetite) colloidal materials.
  • Other nanoparticles useful in the practice of the invention include ZnS, ZnO, TiO 2 , AgI, AgBr, HgI 2 , PbS, PbSe, ZnTe, CdTe, In 2 S 3 , In 2 Se 3 , Cd 3 P 2 , Cd 3 As 2 , InAs, and GaAs.
  • the size of the nanoparticles may be from about 5 nm to about 150 ran (mean diameter), e.g., from about 5 to about 50 nm, or from about 10 to about 30 nm.
  • the nanoparticles may also be rods.
  • Methods of making metal, semiconductor and magnetic nanoparticles are well-known in the art. See, e.g., Schmid, G. (ed.) Clusters and Colloids (VCH, Weinheim, 1994); Hayat, M. A. (ed.) Colloidal Gold: Principles, Methods, and Applications (Academic Press, San Diego, 1991); Massart, IEEE Taransactions On Magnetics, 17:1247 (1981); Ahmadi et al, Science.
  • Suitable nanoparticles are also commercially available from, e.g., Ted Pella, Inc. (gold), Amersham Corporation (gold) and Nanoprobes, Inc. (gold).
  • Gold colloidal particles have high extinction coefficients for the bands that give rise to their colors. The intense colors change with particle size, concentration, interparticle distance, and extent of aggregation and shape (geometry) of the aggregates, making these materials particularly attractive for colorimetric assays. Gold nanoparticles are stable and may readily be modified with thiol functionalities. Exemplary Solid Substrates
  • Suitable substrates include transparent solid surfaces (e.g., glass, quartz, plastics and other polymers), opaque solid surface (e.g., white solid surfaces, such as TLC silica plates, filter paper, glass fiber filters, cellulose nitrate membranes, nylon membranes), and conducting solid surfaces (e.g., indium-tin-oxide (ITO), silicon dioxide (SiO 2 ), silicon oxide (SiO), silicon nitride, etc.)).
  • the substrate can be any shape or thickness, but generally is flat and thin.
  • the substrates are transparent substrates such as glass (e.g., glass slides) or plastics (e.g., wells of microtiter plates).
  • the present invention relates to the detection of metallic nanoparticles on a substrate.
  • the substrate may have a plurality of spots containing specific binding moieties for one or more cardiac troponin related molecules (target analytes).
  • One of the spots on the substrate may be a test spot (containing a test sample) for metallic nanoparticles complexed thereto in the presence of one or more target analytes.
  • Another one of the spots may contain a control spot or second test spot.
  • a method for automatically detecting binding of moieties specific for cardiac troponin to at least some of the spots on the substrate. An image is acquired of the plurality of spots composed of metallic nanoparticles, with or without signal amplification, on the surface of the substrate.
  • the invention provides for methods for detection of gold colloid particles.
  • the nanoparticles are gold nanoparticles (either entirely composed of gold or at least a portion (such as the exterior shell) composed of gold) and amplified with silver or gold deposited post-hybridization on to the gold nanoparticles.
  • the metallic nanoparticles are subject to chemical signal amplification (such as silver amplification).
  • an optimal image is obtained based on an iterative process.
  • Proteins such as cardiac troponin may be contacted with a panel of moieties such as aptamers or antibodies or fragments or derivatives thereof specific for the protein.
  • the antibodies or other binding molecules may be affixed to a solid support such as a chip. Binding of proteins indicative of a particular epitope or isoform of cardie troponin may be verified by binding to a detectably labelled secondary antibody or aptamer.
  • a detectably labelled secondary antibody or aptamer For the labelling of antibodies, it is referred to Harlow and Lane, "Antibodies, A Laboratory Manual", CSH Press, 1988, Cold Spring Harbor.
  • antibodies against the proteins are immobilized on a solid substrate, e.g., glass slides or microtiter plates.
  • the immobilized complexes can be labeled with a reagent specific for the protein(s).
  • the reactants can include enzyme substrates, DNA, receptors, antigens or antibodies to provide, for example, a capture sandwich immunoassay. Any of a variety of known immunoassay methods can be used for detection, including, but not limited to, immunoassay, using an antibody specific for the encoded polypeptide, immunoprecipitation, an enzyme immunoassay, e.g., by enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and the like.
  • ELISA enzyme-linked immunosorbent assay
  • RIA radioimmunoassay
  • immunoassay sensitivity is defined not only by the detection system but by the binding affinities of the antibodies involved, it is possible for other detection methods used in commercially available technologies and also those previously defined in the academic literature but not commercially available to reach the assay sensitivities described in the present specification through the use of antibodies with particular binding affinities, or improvements to the detection method or assay methdology.
  • immunoassay any of a variety of known immunoassay methods can be used for detection, including, but not limited to, immunoassay, using an antibody specific for the encoded polypeptide, e.g., by enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), rolling circe amplification (RCA), immunoPCR (iPCR), magnetic bead based assays that utilize fluorescence and chemiluminescence, electrochemiluminescence and the like; and functional assays for the encoded polypeptide, e.g., binding activity or enzymatic activity.
  • ELISA enzyme-linked immunosorbent assay
  • RIA radioimmunoassay
  • RCA rolling circe amplification
  • iPCR immunoPCR
  • magnetic bead based assays that utilize fluorescence and chemiluminescence, electrochemiluminescence and the like
  • functional assays for the encoded polypeptide e.g., binding activity or enzymatic
  • the detection methods and other methods described herein can be varied. Such variations are within the intended scope of the invention.
  • the probe for use in detection can be immobilized on a solid support, and the test sample contacted with the immobilized probe. Binding of the test sample to the probe can then be detected in a variety of ways, e.g., by detecting a detectable label bound to the test sample.
  • the methods generally include contacting the sample with an antibody specific for one or more forms of cardiac troponin, and detecting binding between the antibody and the one or more forms of cardiac troponin in the sample.
  • the level of antibody binding indicates the susceptibility (at risk for, propensity or affirmative diagnosis) of the patient for a cardiac event. For example, where cardiac troponin levels are present at a level greater than that associated with a negative control level, the patient may be at risk of a cardiac event.
  • Suitable controls include a sample known not to contain cardiac troponin; a sample contacted with an antibody not specific for cardiac troponin; a sample having a level of cardiac troponin associated with MI, UA or NSTEMI, or any combination thereof.
  • the methods include contacting the sample with an antibody specific for the protein of interest (e.g., cTnl) and detecting binding between the antibody and molecules of the sample.
  • the level of antibody binding indicates the susceptibility of the patient to a disease. For example, where the marker polypeptide is present at a level greater than that associated with a negative control level, then the patient is susceptive to disease.
  • one of the binding moieties, e.g., antibody is detectably labeled, either directly or indirectly.
  • Direct labels include radioisotopes; enzymes having detectable products (e.g., luciferase, ⁇ -galactosidase, and the like); fluorescent labels (e.g., fluorescein isothiocyanate, rhodamine, phycoerythrin, and the like); fluorescence emitting metals, e.g., 152 Eu, or others of the lanthanide series, attached to the antibody through metal chelating groups such as EDTA; chemiluminescent compounds, e.g., luminol, isoluminol, acridinium salts, and the like; bioluminescent compounds, e.g., luciferin, aequorin (green fluorescent protein), and the like.
  • Indirect labels include second antibodies specific for antibodies specific for cardiac troponin ("first specific antibody”), wherein the second antibody is labeled as described above; and members of specific binding pairs, e.g., biotin-avidin, and the
  • One of the binding moities may be attached (coupled) to an insoluble support, such as a polystyrene plate or a bead.
  • the sample may be brought into contact with the immobilized antibody and the support washed with suitable buffers followed by contact with a detectably labeled specific antibody.
  • the sample may be brought into contact with and immobilized on a solid support or carrier, such as nitrocellulose, that is capable of immobilizing soluble proteins.
  • the support may then be washed with suitable buffers followed by contacting with an optionally detectably labeled first specific antibody. Detection methods are known in the art and are chosen as appropriate to the signal emitted by the detectable label. Detection is generally accomplished in comparison to suitable controls, and to appropriate standards.
  • the antibody may be attached (coupled) to an insoluble support, such as a polystyrene plate or a bead.
  • Indirect labels include second antibodies specific for antibodies specific for the encoded polypeptide ("first specific antibody"), wherein the second antibody is labeled as described above; and members of specific binding pairs, e.g., biotin-avidin, and the like.
  • the biological sample may be brought into contact with and immobilized on a solid support or carrier, such as nitrocellulose, that is capable of immobilizing cells, cell particles, or soluble proteins.
  • the support may then be washed with suitable buffers, followed by contacting with a detectably-labeled first specific antibody. Detection methods are known in the art and will be chosen as appropriate to the signal emitted by the detectable label. Detection is generally accomplished in comparison to suitable controls, and to appropriate standards.
  • Polypeptide arrays provide a high throughput technique that can assay a large number of polypeptides in a sample. This technology can be used as a tool to test for presence of a marker polypeptide and assessment of cardiac disease. Of particular interest are arrays which comprise a probe for detection of one or more of the marker polypeptides of interest.
  • arrays can be created by spotting binding moieties onto a substrate (e.g., glass, nitrocellulose, and the like) in a two-dimensional matrix or array having bound probes.
  • Arrays also can be created by spotting polypeptide probes onto a substrate in a three-dimensional matrix (e.g. hydrogel) or array having bound probes.
  • the probes can be bound to the substrate by either covalent bonds or by non-specific interactions, such as hydrophobic interactions.
  • Samples of cardiac troponin can be detectably labeled (e.g., using radioactive or fluorescent labels) and then contacted with the binding moieties.
  • the test sample can be immobilized on the array, and the binding moieties detectably labeled and then applied to the immobilized polypeptides.
  • a binding moiety is detectably labeled.
  • the binding moiety is immobilized on the array and not detectably labeled.
  • the sample is applied to the array and bound molecules are detected using labeled binding moieties.
  • the secondary label probes can be introduced in a direct sandwich format where a primary antibody is bound to the substrate, and the secondary antibody is directly attached to the label such as a gold nanoparticle, which "sandwiches" the target protein when both the primary and secondary antibody binds to epitopes of the target.
  • a primary antibody is bound to the substrate
  • the secondary antibody is directly attached to the label such as a gold nanoparticle, which "sandwiches" the target protein when both the primary and secondary antibody binds to epitopes of the target.
  • An alternative methodology well known in the art is to use a secondary antibody in an indirect sandwich assay where the antibody is label with a hapten such as biotin, which can then recognize a streptavidin or avidin molecule which is directly labeled or indirectly labeled.
  • a solid substrate such as a glass or plastic slide, e.g., a microarray slide, magnetic bead, microwell plate or test tube is functionalized with different specific capture moieties (e.g., monoclonal or polyclonal antibodies) capable of specifically isolating the cTn target or form of interest, e.g., using an antibody that binds a defined epitope.
  • a physiological sample is contacted with the functionalized substrate for one or more periods of time. Different incubation times allow for different levels of target detection.
  • one or more nanoparticle-based detection probes functionalized with moieties capable of specific and defined binding to the captured target are added.
  • the signal of each unique capture moiety is detected by, for instance, silver deposition on captured gold containing moieties (array-based assay), the release and detection of unique reporter biobarcode oligonucleotides on an array (biobarcode assay) or the release and detection of variable encoded probes by laser-based flow techniques.
  • the assay results are read by a detection system (e.g., VerigenelD).
  • An algorithm ( Figure 4) may be employed to determine the quantity of total cTn or of each individual moiety and calculate the relative and total results over time. Additional samples may be taken later in time and the results of those additional samples compared to earlier results to determine and report any changes in quantity and/or slope of total and/or specific cTnl forms.
  • the signal in the assay increases with the time allowed for the cTnl in the patient sample to come into contact with the capture antibody on the solid substrate, e.g., the Verigene cartridge.
  • the time required to proceed from Tl, T2 to T3 line depends upon the initial level of cTnl in the patient sample and assay reagents and conditions in the cartridge (time, temperature, buffer, and the like).
  • cTnl For example, as patient presents with chest pain. From an initial blood draw, three sample measurements of cTnl are conducted. Separate cTnl specific solid substrates with the sample are incubated for Tl , T2 and T3 minutes. A signal at Tl on the light grey triangle in Figure IA response line progresses to a signal of T3 on the dark grey square response line.
  • a quick test can be used to rule in AMI, as low pg/mL sensitivity using assays described herein can be obtained with as little as 10 minute target incubation.
  • Samples from patients that are negative on the quick test can be measured at 30 minutes, which is demonstrating sensitivities in the hundreds of fg/mL, enough to measure ACS, UA, and the like, all from one blood draw at time zero.
  • Disease progression can be measured by a subsequent patient sample obtained at a later time and assayed in the same fashion.
  • the higher sensitivity of the current assay such as one employing silver deposition allows ruling in of NSTEMI significantly earlier and ruling in of UA significantly earlier for the small portion that may be identified using current assays a larger portion which would not otherwise be identified with current assays, and in a differentiated fashion from NSTEMIs for time points later than that needed for 100% NSTEMI sensitivity (e.g., 2 hours) the assay also allows ruling out normals significantly earlier by achieving near 100% sensitivity for ACS not otherwise possible.
  • the assay may provide for the ability to distinguish between NSTEMI, UA, ACS, and AMI, based on the different forms of troponin that are present in the sample.
  • the use of the current assay provides ruling in of NSTEMI significantly earlier and ruling in of UA significantly earlier for the small portion that may be identified using current assays a larger portion which would not otherwise be identified with current assays, and in a differentiated fashion from NSTEMIs for time points later than that needed for 100% NSTEMI sensitivity (e.g., 2 hours) ruling in of UA and in a differentiated fashion from NSTEMIs using two time points (e.g., 2 hours); and ruling out normals significantly earlier by achieving near 100% sensitivity for ACS, not otherwise possible, using not only values but the slopes of concentrations (Figure 1C).
  • Figure 2 shows results for differential measurement of cTnl epitopes using selected specific antibodies.
  • a cTnl sample is introduced to an array of antibodies with known specificities for various parts of the cTnl molecule, or different forms of the cTnl molecule.
  • a probe or probes functionalized with antibody or antibodies to complementary parts of the molecules of interest are introduced. Capture of the probe(s) and the signal generated depends on the absence, presence and/or quantity of the cTnl molecules, parts or modifications of interest.
  • the dotted line indicates accumulation of total cTnl products over time.
  • Straight lines indicate accumulation of various cTnl forms over time.
  • Curved lines indicate change in distribution of various cTnl forms over time.
  • Squiggle lines indicate present limits of detection for standard assays. El, E2, E3 correlate with various disease states, allowing more complete diagnoses.
  • a patient sample is split and added to each of two solid supports, for instance, cartridges in Verigene System (see U.S. Patent No. 7,110,585, which is incorporated herein by reference).
  • the first test result is determined in a few minutes. If negative, sensitive test results determined after longer incubation are needed. Total results and individual forms of troponin (Metabolite Profile) are also reported. Repeat for additional time points to measure changes in troponin forms over time.
  • the invention also provides a variety of computer-related embodiments. Specifically, the automated means for performing the methods described above may be controlled using computer-readable instructions, i.e., programming. Accordingly, in some embodiments the invention provides computer programming for analyzing and comparing protein patterns present in a sample, wherein the comparing indicates the presence or absence of a disease.
  • the invention provides computer programming for analyzing and comparing a first and second protein patterns from samples taken from a subject in at least two different time points, wherein the first pattern is indicative of a disease.
  • the comparing provides for monitoring of the progression of the disease from the first time point to the second time point.
  • the methods and systems described herein can be implemented in numerous ways. In one embodiment of particular interest, the methods involve use of a communications infrastructure, for example the internet. Several embodiments of the invention are discussed below. It is also to be understood that the present invention may be implemented in various forms of hardware, software, firmware, processors, or a combination thereof. The methods and systems described herein can be implemented as a combination of hardware and software.
  • the software can be implemented as an application program tangibly embodied on a program storage device, or different portions of the software implemented in the user's computing environment (e.g., as an applet) and on the reviewer's computing environment, where the reviewer may be located at a remote site (e.g., at a service provider's facility).
  • portions of the data processing can be performed in the user-side computing environment.
  • the user-side computing environment can be programmed to provide for defined test codes to denote platform, carrier/diagnostic test, or both; processing of data using defined flags, and/or generation of flag configurations, where the responses are transmitted as processed or partially processed responses to the reviewer's computing environment in the form of test code and flag configurations for subsequent execution of one or more algorithms to provide a results and/or generate a report in the reviewer's computing environment.
  • the application program for executing the algorithms described herein may be uploaded to, and executed by, a machine comprising any suitable architecture.
  • the machine involves a computer platform having hardware such as one or more central processing units (CPU), a random access memory (RAM), and input/output (I/O) interface(s).
  • the computer platform also includes an operating system and microinstruction code.
  • the various processes and functions described herein may either be part of the microinstruction code or part of the application program (or a combination thereof) which is executed via the operating system.
  • various other peripheral devices may be connected to the computer platform such as an additional data storage device and a printing device.
  • the system generally includes a processor unit.
  • the processor unit operates to receive information, which generally includes test data (e.g., protein levels or patterns tested), and test result data (e.g., the levels of specific proteins within a sample).
  • This information received can be stored at least temporarily in a database, and data analyzed in comparison to a library of known protein patterns to be indicative of the presence or absence of a disease.
  • Part or all of the input and output data can also be sent electronically; certain output data (e.g., reports) can be sent electronically or telephonically (e.g., by facsimile, e.g., using devices such as fax back).
  • Exemplary output receiving devices can include a display element, a printer, a facsimile device and the like.
  • Electronic forms of transmission and/or display can include email, interactive television, and the like.
  • all or a portion of the input data and/or all or a portion of the output data are maintained on a server for access, preferably confidential access. The results may be accessed or sent to professionals as desired.
  • a system for use in the methods described herein generally includes at least one computer processor (e.g., where the method is carried out in its entirety at a single site) or at least two networked computer processors (e.g., where protein pattern data for a sample obtained from a subject is to be input by a user (e.g., a technician or someone performing the activity assays)) and transmitted to a remote site to a second computer processor for analysis (e.g., where the protein pattern data is compared to a library of protein patterns known to be indicative of the presence or absence of a cardiac disease), where the first and second computer processors are connected by a network, e.g., via an intranet or internet).
  • a network e.g., via an intranet or internet
  • the system can also include a user component(s) for input; and a reviewer component(s) for review of data, and generation of reports, including detection of disease, differential diagnosis or monitoring the progression of a disease.
  • Additional components of the system can include a server component(s); and a database(s) for storing data (e.g., as in a database of report elements, e.g., a library of protein patterns known to be indicative of the presence or absence of a disease, or a relational database (RDB) which can include data input by the user and data output.
  • the computer processors can be processors that are typically found in personal desktop computers (e.g., IBM, Dell, Macintosh), portable computers, mainframes, minicomputers, or other computing devices.
  • the networked client/server architecture can be selected as desired, and can be, for example, a classic two or three tier client server model.
  • a relational database management system (RDMS) either as part of an application server component or as a separate component (RDB machine) provides the interface to the database.
  • the architecture is provided as a database-centric user/server architecture, in which the user application generally requests services from the application server which makes requests to the database (or the database server) to populate the activity assay report with the various report elements as required, especially the assay results for each activity assay.
  • the server(s) e.g., either as part of the application server machine or a separate RDB/relational database machine) responds to the user's requests.
  • the input components can be complete, stand-alone personal computers offering a full range of power and features to run applications.
  • the user component usually operates under any desired operating system and includes a communication element (e.g., a modem or other hardware for connecting to a network), one or more input devices (e.g., a keyboard, mouse, keypad, or other device used to transfer information or commands), a storage element (e.g., a hard drive or other computer- readable, computer-writable storage medium), and a display element (e.g., a monitor, television, LCD, LED, or other display device that conveys information to the user).
  • the user enters input commands into the computer processor through an input device.
  • the user interface is a graphical user interface (GUI) written for web browser applications.
  • GUI graphical user interface
  • the server component(s) can be a personal computer, a minicomputer, or a mainframe and offers data management, information sharing between clients, network administration and security.
  • the application and any databases used can be on the same or different servers.
  • the database(s) is usually connected to the database server component and can be any device which will hold data.
  • the database can be any magnetic or optical storing device for a computer (e.g., CDROM, internal hard drive, tape drive).
  • the database can be located remote to the server component (with access via a network, modem, etc.) or locally to the server component.
  • the database can be a relational database that is organized and accessed according to relationships between data items.
  • the relational database is generally composed of a plurality of tables (entities). The rows of a table represent records (collections of information about separate items) and the columns represent fields (particular attributes of a record).
  • the relational database is a collection of data entries that "relate" to each other through at least one common field.
  • Additional workstations equipped with computers and printers may be used at point of service to enter data and, in some embodiments, generate appropriate reports, if desired.
  • the computer(s) can have a shortcut (e.g., on the desktop) to launch the application to facilitate initiation of data entry, transmission, analysis, report receipt, etc. as desired.
  • FIG 8 is a logical block diagram of a computing environment 800 according to an example embodiment.
  • the computing environment 800 includes an application server 812 accessible by client computing devices 802, 804, 806 over a network 808 via a web server 814.
  • the application server 812 provides services to requesting a requesting client 802, 804, 806. Services may be requested over the network 808 via web pages, applications, or processes of the client 802, 804, 806.
  • the application server 812 may receive a request from the web server 810 that originated with one of the clients 802, 804, 806.
  • the request may be a request to detect an acute coronary syndrome as a function of two input values which may be provided with the request.
  • the service of the application server may be operable to receive first and second inputs indicative of detected amounts of cardiac troponin concentrations which may include cardiac troponin concentrations less than 10 pg/mL.
  • the service may then evaluate the first and second inputs as a function of one or more algorithms to identify one or more cardiac conditions of the particular test subject, such as a test subject.
  • the service may then provide an output indicative of the one or more identified cardiac conditions.
  • the computing environment 800 may also include a database 814.
  • the service of the application server 812 may access data from and store data to the database 814.
  • the one or more algorithms to identify one or more cardiac conditions of the particular test subject may be retrieved from the database 814.
  • the input received in a client request and an output provided in response to a request may also be stored in the database 814.
  • the stored algorithms may include algorithms encoded in computer executable code, such as a computer program or module, to perform one or more of the methods described herein.
  • Such algorithms may detect cardiac conditions as a function of the two inputs, or one or more than two inputs, to detect such coronary positions as acute coronary syndrome, unstable angina, non-ST elevation myocardial infarction, a normal cardiac condition.
  • Figure 9 is a block diagram of a computing device according to an example embodiment.
  • multiple such computer systems are utilized in a distributed network to implement multiple components in a transaction based environment.
  • An object oriented, service oriented, monolithic, or other architecture may be used to implement such functions and communicate between the multiple systems and components.
  • One example computing device in the form of a computer 910 may include a processing unit 902, memory 904, removable storage 912, and non-removable storage 914.
  • Memory 904 may include volatile memory 906 and non- volatile memory 908.
  • Computer 910 may include - or have access to a computing environment that includes - a variety of computer-readable media, such as volatile memory 906 and non- volatile memory 908, removable storage 912 and non-removable storage 914.
  • Computer storage includes random access memory (RAM), read only memory (ROM), erasable programmable read-only memory (EPROM) & electrically erasable programmable read-only memory (EEPROM), flash memory or other memory technologies, compact disc read-only memory (CD ROM), Digital Versatile Disks (DVD) or other optical disk storage, magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices, or any other medium capable of storing computer-readable instructions.
  • Computer 910 may include or have access to a computing environment that includes input 916, output 918, and a communication connection 920.
  • the computer may operate in a networked environment using a communication connection to connect to one or more remote computers, such as database servers.
  • the remote computer may include a personal computer (PC), server, router, network PC, a peer device or other common network node, or the like.
  • the communication connection may include a Local Area Network (LAN), a Wide Area Network (WAN) or other networks.
  • LAN Local Area Network
  • WAN Wide Area
  • Computer-readable instructions stored on a computer-readable medium are executable by the processing unit 902 of the computer 910.
  • a hard drive, CD- ROM, and RAM are some examples of articles including a computer-readable medium.
  • a computer program 925 capable of implementing one or more of the methods described herein to identify various cardiac conditions, identify a condition as a function of various protein patterns, and other methods. An example of one such method is illustrated and described with regard to FIG. 10.
  • FIG 10 is a block flow diagram of a computerized method 1000 according to an example embodiment.
  • the computerized method 1000 is a method that may be performed by a computer application executing on a stand alone computer, on a server accessible to client computing devices, or in a number of other device and networked computing environments.
  • the method 1000 is an example method that may be performed to identify a cardiac condition of a test subject, such as a test subject, based on results of a number of tests.
  • the method 1000 may include receiving 1002 first and second inputs indicative of detected amounts of complexes in first and second physiological fluid samples taken at respective first and second time points from a test subject.
  • the computerized method 1000 further includes evaluating 1004 the first and second inputs as a function of one or more algorithms to identify one or more cardiac conditions of the test subject.
  • An output indicative of the one or more identified cardiac conditions of the test subject may then be provided 1006.
  • the output may be provided 1006 as a displayed output on a monitor or other display device. In other embodiments, the output may be provided as a data value from a process executing on a server.
  • the amount of complexes are detected and received from a device that detects the complex amounts in the first and second physiological fluid samples by forming the complexes by contacting the physiological fluid samples and a solid substrate having one or more cardiac- troponin specific antibodies.
  • Example 1 cTnl assay sensitivity as a function of time
  • Detection of the gold particle labeled troponin was achieved by catalytically reducing silver onto the surface of the gold particles followed by imaging light scattered by the silver amplified gold particles using a surface scanner such as a Tecan LS (Tecan USA) or a Verigene ID (Nanosphere, Northbrook, IL) detection system. These data demonstrate that different levels of sensitivity are achieved by incubating the sample containing cTnl target for different periods of time.
  • a surface scanner such as a Tecan LS (Tecan USA) or a Verigene ID (Nanosphere, Northbrook, IL) detection system.
  • the nanoparticle-based assay quantifies an optical signal resulting from selective detection of the cTnl molecule through analyte-specific capture of gold nanoparticle probes, followed by subsequent signal enhancement.
  • capture antibody mouse monoclonal, Nanogen
  • CodeLink activated microarray slides along with controls in ten sub-arrays and assembled into a hybridization chamber. Fifty microliters of sample was incubated for 90 minutes at 35°C.
  • FIG. 1A Three sample measurements of cTnl were started from an initial blood draw using the described ultrasensitive cTnl assay.
  • a signal at Tl on the light grey triangle response line progresses to a signal of T3 on the dark grey square response line.
  • a quick test (10 minute target incubation) can be used to rule in AMI (data not shown). Patients that are negative on the quick test can be measured on the 30 minute target incubation test (Tl), which has sensitivities in the hundreds of fg/mL, enough to measure ACS, UA, etc., all from one blood draw at time zero.
  • Disease progression can be measured by a subsequent patient sample obtained at a later time (e.g., T2 or T3) and assayed in the same fashion.
  • a later time e.g., T2 or T3
  • the higher sensitivity of the nanoparticle-based assay enables ruling in of NSTEMI significantly earlier; ruling in of UA: i. ignificantly earlier for the small portion that may be identified using current assays, ii. an additional larger portion which would not otherwise be identified with current assays, iii. in a differentiated fashion from NSTEMIs for time points later than that needed for 100% NSTEMI sensitivity (e.g., 2 hours); and ruling out normals significantly earlier by achieving near 100% sensitivity for ACS not otherwise possible.
  • Figure 1C illustrates changes in troponin values from serial blood draws which were detected earlier by the higher-sensitivity assay described herein, including the concept of "sensitivity maturation" which increases sensitivity for each individual blood draw by using a longer incubation time as described above.
  • the use of this assay to measure cTnl as shown allows for ruling in of NSTEMI significantly earlier; and ruling in of UA significantly earlier for the small portion that may be identified using current assays, to rule in an additional larger portion which would not otherwise be identified with current assays, in a differentiated fashion from NSTEMIs using two time points (e.g., 2 hours), and ruling out normals significantly earlier by achieving near 100% sensitivity for ACS, not otherwise possible, using not only values but the slopes of concentrations.
  • the assay may distinguish between NSTEMI, UA, ACS, AMI, etc. based on the different forms of troponin that are present in the sample.
  • Figures IB-D the distributions of patient population for each disease type are shown to change between time points.
  • the lower cutoffs (shown by dotted horizontal lines in Figures IB-D) can be used for earlier risk assessment or diagnosis of patients using the ultrasensitive assay.
  • slopes are shown by arrows from one time point to another for the same individual or population in Figures 1C and ID. The slope can be used for earlier risk assessment or diagnosis of patients using the ultrasensitive assay.
  • the cutoff and slope measurements also can be used to differentiate one population, risk group or diagnosis from another.
  • a cTnl sample (50 pg/mL of cTnl NIST standard spiked into troponin depleted serum) was introduced to an array of anti-troponin antibodies deposited on Codelink substrates (labeled Capture Ab), Figure 2.
  • the capture antibodies have known specificities for various parts of the cTnl molecule, or different forms of the cTnl molecule, Figure 2.
  • a probe or probes functionalized with antibody to complementary parts of the molecules of interest were introduced.
  • the secondary antibodies were attached to 13 nm diameter gold particles and introduced in separate assays.
  • Each of the anti-troponin secondary antibodies (labeled probe Ab) binds to a unique epitope of the cTnl molecule. Capture of the probe(s) and the signal generated depends on the absence, presence and/or quantity of the cTnl molecules, parts or modifications of interest. This experiment demonstrates that different combinations of antibodies uniquely detect this specific form of cTnl.
  • Figure 4 further illustrates a multi-timepoint, multi-metabolite diagnostic algorithm which may be used in conjunction with the epitope specific assay format for predictive diagnosis of cardiac events.
  • the patient sample is split into two assays which are performed for different incubation periods (Stat test and sensitive test in Figure 4).
  • the two assays can be performed in two cartridges on the Verigene system (see U.S. Patent No. 7,110,585, which is incorporated herein by reference).
  • Stat test results are determined in a few minutes. If negative, refer to sensitive test results determined after longer incubation.
  • Total results and individual forms of troponin (Metabolite Profile) are reported. Repeat for additional time points to measure changes in troponin forms over time.
  • Cardiac troponin detects myocardial necrosis and defines myocardial infarction (MI) when concentrations are increased above the 99th percentile in patients with symptoms of ischemia (Thygesen et al., Europ. Heart J., 28:2525 (2007)).
  • the current generation of cTn assays has demonstrated 99 l percentiles ranging from 0.025 to 0.06 ⁇ g/L with lower limits of detection to 0.006 ⁇ g/L (Jaffe et al., J. Am. Coll. Cardiol.. 48:1 (2006); Apple et al., Clin. Chem., 53:1558 (2007)).
  • capture antibody mouse monoclonal, Nanogen
  • CodeLink activated microarray slides along with controls in ten sub-arrays and assembled into a hybridization chamber. Fifty microliters of sample was incubated for 90 minutes at 35°C. Wells were washed with 0.3% Tween 20 in phosphate- buffered saline (PBS) pH 7.4, then incubated with detection antibody (rabbit polyclonal, Nanogen) in 1% BSA, 0.3% Tween in PBS pH 7.4 and incubated for 20 minutes. Wells were washed again, then incubated in 150 pM gold nanoparticles for 10 minutes.
  • PBS phosphate- buffered saline
  • the limit of detection (LoD) of the nanoparticle-based cTnl assay was 0.2 pg/mL.
  • the linear range was 0.2 to 500 pg/mL.
  • Imprecision (%CV) was 16.0% at 0.05 pg/mL, 9.5% at 0.5 pg/mL and 9.7% at 5 pg/mL.
  • Figure 5 shows that 45% of the normal subjects had a measurable concentration, with a 99th percentile of 2.8 pg/mL.
  • the assay measured cTnl concentrations that were 1 to 2 orders of magnitude lower than the commercial assays.
  • a cohort of 50 patients were identified with ischemic chest pain at rest and serial negative cTnl results performed in the TIMI Biomarker Core Laboratory (Boston, MA) using a current commercial assay (Figure 11).
  • 50 patients were identified with definite myocardial injury in whom the initial current generation cTnl result was negative but results from sampling at 6-8 hours or 18-24 hours revealed a subsequent increase in cTnl.
  • the nanoparticle-based assay quantifies an optical signal resulting from selective detection of the cTnl molecule through analyte-specific capture of gold nanoparticle probes, followed by subsequent signal enhancement.
  • capture antibody mouse monoclonal, Nanogen
  • CodeLink activated microarray slides along with controls in ten sub-arrays and assembled into a hybridization chamber. Fifty microliters of sample was incubated for 90 minutes at 35°C. Wells were washed with 0.3% Tween 20 in phosphate- buffered saline (PBS) pH 7.4, then incubated with detection antibody (rabbit polyclonal, Nanogen) in 1% BSA, 0.3% Tween in PBS pH 7.4 and incubated for 20 minutes. Wells were washed again, then incubated in 150 pM gold nanoparticles for 10 minutes. Slides were washed, followed by a 150 mM sodium nitrate, pH 7.5 wash. Capture substrates were immersed in signal enhancement reaction mix for 9 minutes at 19°C, and rinsed. Slides were dried and scanned (see Example 1). Results
  • nano-cTnl The clinical sensitivity of an ultra-sensitive nanoparticle-based cTnl assay (detection limit of 0.00015 ng/mL, referred to as nano-cTnl) was assessed in the 50 patients with UA (serial negative cTnl) and 50 patients with NSTEMI with an initially negative current generation cTnl. Measured at 0, 2 and 8 hours with the nano-cTnl assay (i.e., ultrasensitive cTnl assay), 54%, 78% and 90% of patients with unstable angina defined by a current commercial assay had an elevated nano- cTnl result (>0.002 ng/mL, 99% percentile decision-limit, CV ⁇ 15%) ( Figure 6A).
  • the nanoparticle assay is based on the quantification of an optical signal resulting from selective detection of the cTnl molecule through analyte-specific capture of gold nanoparticle probes, followed by subsequent signal enhancement.
  • capture antibody mouse monoclonal, Nanogen
  • CodeLink activated microarray slides along with controls in ten sub- arrays and assembled into a hybridization chamber. Fifty microliters of sample was incubated for 90 minutes at 35°C.
  • the target troponin antigen was incubated in 1 % rat serum on the slide surface, followed by labeling with a biotinylated rabbit anti-troponin antibody in a sandwich assay format.
  • the sandwich complex was further labeled with streptavidin, followed by binding of 13 nm diameter gold particles with covalently immobilized biotins attached to the surface. Detection of the labeled troponin was achieved by catalytically reducing silver onto the surface of the gold particles followed by imaging light scattered by the silver amplified gold particles (Storhoff et al. (Biosens. & Bioelectron., 19:875 (2004)).
  • the mean signal intensity was measured as a function of rat cTnl concentration by adding known amounts of rat troponin I (10 - 2500 fg/mL) into the rat serum.
  • rat troponin I 10 - 2500 fg/mL

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention porte sur des procédés et un appareil d'évaluation d'un risque cardiaque et d'une ischémie par la détection ou l’analyse des taux de troponine cardiaque. L'invention porte également sur des procédés de détection de faibles taux de troponine cardiaque dans des échantillons de fluide physiologique.
EP08825246A 2008-10-11 2008-10-11 Procédés et analyses d'évaluation d'un risque cardiaque et d'une ischémie Withdrawn EP2348968A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/079665 WO2010042126A1 (fr) 2008-10-11 2008-10-11 Procédés et analyses d'évaluation d'un risque cardiaque et d'une ischémie

Publications (2)

Publication Number Publication Date
EP2348968A1 true EP2348968A1 (fr) 2011-08-03
EP2348968A4 EP2348968A4 (fr) 2012-06-20

Family

ID=42100870

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08825246A Withdrawn EP2348968A4 (fr) 2008-10-11 2008-10-11 Procédés et analyses d'évaluation d'un risque cardiaque et d'une ischémie

Country Status (2)

Country Link
EP (1) EP2348968A4 (fr)
WO (1) WO2010042126A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012020045A1 (fr) * 2010-08-10 2012-02-16 Roche Diagnostics Gmbh Procédé de sélection de patients atteints d'une maladie des artères coronaires stabilisée en vue d'une icp ou d'un traitement médical
CN102207507A (zh) * 2011-03-24 2011-10-05 武汉璟泓万方堂医药科技有限公司 心肌肌钙蛋白半定量检测试纸及制备方法
DE102012223378A1 (de) * 2012-12-17 2014-06-18 Charité - Universitätsmedizin Berlin In-vitro Verfahren und Kit zur Diagnose von akutem Koronarsyndrom
EP4076401A4 (fr) * 2019-12-18 2024-01-17 Wisconsin Alumni Research Foundation Dosage de troponine i cardiaque précis et complet activé par nanotechnologie et protéomique

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114947A2 (fr) * 2006-04-04 2007-10-11 Singulex, Inc. Système et procédés hautement sensibles destinés à une analyse de la troponine
WO2008073046A1 (fr) * 2006-12-12 2008-06-19 Scientific Engeneering Qed Procédé de détermination d'un état de santé par des substances d'analyse

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7572640B2 (en) * 2004-09-28 2009-08-11 Singulex, Inc. Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
US9040305B2 (en) * 2004-09-28 2015-05-26 Singulex, Inc. Method of analysis for determining a specific protein in blood samples using fluorescence spectrometry
EP1890153A1 (fr) * 2006-08-16 2008-02-20 F. Hoffman-la Roche AG Troponine cardiaque servant d'indicateur de maladie avancée des artères coronaires

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114947A2 (fr) * 2006-04-04 2007-10-11 Singulex, Inc. Système et procédés hautement sensibles destinés à une analyse de la troponine
WO2008073046A1 (fr) * 2006-12-12 2008-06-19 Scientific Engeneering Qed Procédé de détermination d'un état de santé par des substances d'analyse

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010042126A1 *

Also Published As

Publication number Publication date
WO2010042126A1 (fr) 2010-04-15
EP2348968A4 (fr) 2012-06-20

Similar Documents

Publication Publication Date Title
Fathil et al. Diagnostics on acute myocardial infarction: Cardiac troponin biomarkers
Wu et al. Biomedical and clinical applications of immunoassays and immunosensors for tumor markers
JP4927825B2 (ja) 初期段階の心機能異常を診断または予測するための装置および方法
JP2012514184A (ja) 多重分析物の検出及び定量化のための方法
JP2011523051A (ja) １型糖尿病におけるバイオマーカーとしてのｇｄｆ−１５
JP6412085B2 (ja) トロポニンおよびｂｎｐに基づく発作のリスク患者および原因の診断
de Ávila et al. Disposable electrochemical magnetoimmunosensor for the determination of troponin T cardiac marker
US20130217147A1 (en) Detection of complexes of tau and amyloid
JP2011501113A (ja) 急性冠症候群を有する患者での既存の心筋機能不全の評価のためのナトリウム利尿ペプチド／トロポニン比
Timilsina et al. Biofabrication of multiplexed electrochemical immunosensors for simultaneous detection of clinical biomarkers in complex fluids
US20090233312A1 (en) Methods and assays to assess cardiac risk and ischemia
US10386363B2 (en) Assay
WO2010042126A1 (fr) Procédés et analyses d'évaluation d'un risque cardiaque et d'une ischémie
Ma et al. The role of antibody-based troponin detection in cardiovascular disease: A critical assessment
JP2008507686A (ja) リウマチ様関節炎（ｒａ）のためのバイオマーカー
Pelkkikangas et al. Simple, rapid, and sensitive thyroid-stimulating hormone immunoassay using europium (III) nanoparticle label
Gao et al. Development of a novel homogeneous nanoparticle-based assay for rapid and high-throughput quantitation of the sST2 protein in human serum
JP2019502933A (ja) 不安定狭心症の診断
Wani et al. New analytical application of antibody-based biosensor in estimation of thyroid-stimulating hormone in serum
Clarke et al. Immunoassays
US20190376984A1 (en) Methods for quantifying soluble amyloid beta and amyloid beta oligomers
Liu et al. Detection of biomarkers of acute myocardial infarction by high-throughput suspension array technology in serum sample
Meibodi et al. Development of an enhanced chemiluminescence immunoassay (CLIA) for detecting urinary albumin
Lin et al. Development of a qualitative sequential immunoassay for characterizing the intrinsic properties of circulating cardiac troponin I
Jiang et al. High-sensitivity cardiac troponins I sandwich assay by immunomagnetic microparticle and quantum dots

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110511

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20120522

RIC1 Information provided on ipc code assigned before grant

Ipc: A61B 5/02 20060101AFI20120515BHEP

Ipc: G01N 33/58 20060101ALI20120515BHEP

Ipc: G01N 33/68 20060101ALI20120515BHEP

17Q First examination report despatched

Effective date: 20130115

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140501